The following stories appear in full on today's Vidyya Medical News Service Web site.
Novartis would like to inform health professionals of recent changes to the WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of the prescribing information (PI) for Exelon® (rivastigmine tartrate). These changes provide guidelines for reinitiating therapy in patients who have interrupted treatment with Exelon to reduce the risk of severe vomiting.
For more information: Safety Warning Issued: Exelon®, Novartis' Medication For The Treatment Of Alzheimer's Disease
Exelon (rivastigmine tartrate) is manufactured and marketed by Novartis Pharmaceuticals. The drug is used for the treatment of symptoms related to Alzheimer's disease. Get newly updated prescribing information for the drug in today's issue. This information is being released too late to make it into this year's PDR, so Vidyya readers may wish to make a note that the information is available on our service.
For more information: Prescribing Information: Exelon
The US Federal government and the American Heart Association including its division the American Stroke Association are joining forces in the fight against heart disease and stroke, America's number one and number three killers, respectively. Several Federal health agencies and the association signed a Memorandum of Understanding (MOU) to speed progress toward the heart disease and stroke goals set forth in Healthy People 2010, a national health promotion and disease prevention initiative.
For more information: Federal Health Agencies Team Up With The American Heart Association To Advance War On Heart Disease And Stroke
Dengue outbreaks have been reported in communities along the Mexico--US border since 1980; however, during 1987--July 1999, no cases were reported from Laredo, Texas (1999 population: 162,000). To determine whether undiagnosed or unreported dengue cases had occurred in Laredo, the Texas Department of Health (TDH) reviewed medical records from five Laredo health facilities (the two city hospitals and the three largest of five community clinics). This report summarizes the findings of the review, which indicated that during July 23--August 20, 1999, 50% of suspected case-patients had undiagnosed dengue infection.
For more information: Underdiagnosis Of Dengue
Vidyya is pleased to reprint the latest on bovine spongiform encephalopathy from the Emerging Infectious Diseases Journal (EID), January-February 2001. The epidemic of bovine spongiform encephalopathy in the United Kingdom, which began in 1986 and has affected nearly 200,000 cattle, is waning to a conclusion, but leaves in its wake an outbreak of human Creutzfeldt-Jakob disease, most probably resulting from the consumption of beef products contaminated by central nervous system tissue. Although averaging only 10-15 cases a year since its first appearance in 1994, its future magnitude and geographic distribution (in countries that have imported infected British cattle or cattle products, or have endogenous BSE) cannot yet be predicted. The possibility that large numbers of apparently healthy persons might be incubating the disease raises concerns about iatrogenic transmissions through instrumentation (surgery and medical diagnostic procedures) and blood and organ donations. Government agencies in many countries continue to implement new measures to minimize this risk.
For more information: Bovine Spongiform Encephalopathy And Variant Creutzfeldt-Jakob Disease: Background, Evolution, And Current Concerns
Today's Vidyya articles are:
As always, we hope you enjoy the issue.